Search - tctmd.com

Displaying 21 - 40 of 309

Sort: Relevancy | Date

Presentation TCT 2016

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Presenter: William A. Gray, Stephan Windecker

October 31, 2016

Presentation TCT 2016

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Presenter: William A. Gray, Stephan Windecker, Vinod H. Thourani

October 31, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Michael J. Mack

October 30, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Daily News

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Caitlin E. Cox

October 04, 2016

News Daily News

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

Caitlin E. Cox

October 04, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Shelley Wood

September 13, 2016

News Daily News

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

Shelley Wood

September 13, 2016

News Conference News ESC 2016

New ESC A-fib Guidelines Call for Integrated Care for All Patients

Todd Neale

August 27, 2016

News Opinion Editor's Corner

ESC 2016: Bare-Metal Flashbacks, Coronary Imaging Comparisons, Heart Team Hype, and His Holiness

Shelley Wood

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

CLEAN-TAVI:TAVR 脑栓塞预防结果公布

Yael L. Maxwell

August 15, 2016

News Daily News

CLEAN-TAVI: Se Publican los Resultados de Protección Embólica Cerebral en TAVR

Yael L. Maxwell

August 15, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

Presentation TVT 2016

PARTNER Echocardiography Observations on Valve Durability

Presenter: Rebecca T. Hahn

June 17, 2016

News Conference News TVT 2016

What TAVR Needs Next . . . and What It’s Getting

Shelley Wood

June 17, 2016

Presentation TVT 2016

Study Design for the PARTNER 3 Low-Risk Trial

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

Highlights From PARTNER 2A in Intermediate-Risk Patients

Presenter: Michael J. Mack

June 16, 2016

Advertisement

PARTNER 2 and SAPIEN 3 Critique: Pros and Cons

Trial #6 - The Essentials ofPARTNER 2 and SAPIEN 3 - TAVR In Intermediate Risk Patients, and Improved TAVR Devices

Low-Risk Studies: Design and Updates II - The PARTNER 3 Low-Risk Trial

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

TAVR 3 年后瓣膜性能持稳，大多数死亡非心脏相关：FRANCE 2 登记表

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

New ESC A-fib Guidelines Call for Integrated Care for All Patients

ESC 2016: Bare-Metal Flashbacks, Coronary Imaging Comparisons, Heart Team Hype, and His Holiness

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

CLEAN-TAVI:TAVR 脑栓塞预防结果公布

CLEAN-TAVI: Se Publican los Resultados de Protección Embólica Cerebral en TAVR

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

PARTNER Echocardiography Observations on Valve Durability

What TAVR Needs Next . . . and What It’s Getting

Study Design for the PARTNER 3 Low-Risk Trial

Highlights From PARTNER 2A in Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content